What happens when you take grapefruit with lurasidone?
Lurasidone (brand name Latuda) is an atypical antipsychotic FDA-approved for schizophrenia and for bipolar depression, both as monotherapy and as adjunctive therapy with lithium or valproate. It is metabolized almost exclusively by CYP3A4. Two of its main metabolites, ID-14283 and ID-14326, are pharmacologically active, but the parent drug is responsible for the majority of clinical effect.
Grapefruit juice contains furanocoumarins, including bergamottin and 6,7-dihydroxybergamottin, that irreversibly inactivate the CYP3A4 enzyme in the lining of the small intestine. Until new enzyme protein is synthesized over 24 to 72 hours, oral CYP3A4 substrates escape first-pass metabolism and reach the bloodstream in higher concentrations than the label predicts.
The Latuda prescribing information states explicitly that 'grapefruit and grapefruit juice should be avoided in patients taking LATUDA, since these may inhibit CYP3A4 and alter LATUDA concentrations.' The label also recommends not exceeding 20 mg/day with moderate CYP3A4 inhibitors (like diltiazem) and contraindicates strong CYP3A4 inhibitors (like ketoconazole, itraconazole, clarithromycin, ritonavir) entirely, which contextualizes how seriously the manufacturer treats grapefruit.
Why is this important?
Lurasidone is dose-dependently associated with akathisia (inner restlessness), somnolence, parkinsonism, dystonia, orthostatic hypotension, nausea, and modest QTc prolongation. The recommended dose range is 20 to 160 mg/day, with most patients responding between 40 and 120 mg. Even at label-recommended doses, somnolence and akathisia are common.
Raising lurasidone exposure with grapefruit pushes patients further along this dose-response curve without the prescriber knowing. The increase is unpredictable. Furanocoumarin content varies between fruits, brands of juice, and individual servings. The result is that one patient might tolerate the combination while another develops disabling akathisia, restless leg-like symptoms, severe sedation, or orthostatic falls.
The interaction is especially relevant because lurasidone is often prescribed for bipolar depression in patients who are also taking antidepressants, lithium, or valproate; for elderly patients with dementia-related psychosis (off-label) who are highly sensitive to sedation and falls; and for adolescents (age 13 to 17 for schizophrenia, 10 to 17 for bipolar depression) who may be unaware of food-drug interactions.
What should you do?
Avoid grapefruit, grapefruit juice, pomelo (also called Chinese grapefruit), Seville (sour) oranges, tangelos, and minneolas completely while taking lurasidone. Be alert to marmalade made with Seville oranges and to citrus blend beverages. Sweet oranges, mandarins, clementines, lemons, and limes are safe.
Take lurasidone with food (at least 350 calories). Food substantially increases the absorption of lurasidone and is required for the drug to work properly. If you replace your morning juice habit with sweet orange juice or apple juice taken together with a real meal, the dose works as labeled and you avoid the grapefruit interaction.
If you accidentally consume grapefruit and notice new restlessness, an urge to move constantly, stiffness, drooling, tremor, fainting on standing, or excessive sleepiness, contact your prescriber. Do not stop lurasidone abruptly; the prescriber will adjust the dose or schedule.
Tell every prescriber and pharmacist that you take lurasidone, because adding any moderate or strong CYP3A4 inhibitor on top of accidental grapefruit exposure is a serious problem.
Which specific products are affected?
All Latuda tablet strengths (20 mg, 40 mg, 60 mg, 80 mg, 120 mg) are affected, as are generic lurasidone tablets in the same strengths. The interaction is at the intestinal CYP3A4 enzyme and applies to any swallowed dose.
Within the atypical antipsychotic class, grapefruit interactions vary widely. Quetiapine (Seroquel), ziprasidone (Geodon), iloperidone (Fanapt), pimavanserin (Nuplazid), cariprazine (Vraylar), and brexpiprazole (Rexulti) are also CYP3A4 substrates with relevant grapefruit interactions. Aripiprazole (Abilify) is partially affected. Olanzapine (Zyprexa), clozapine (Clozaril), risperidone (Risperdal), and paliperidone (Invega) are less affected because they rely more on other enzymes (CYP1A2, CYP2D6).
The bottom line
Latuda's FDA label specifically tells patients to avoid grapefruit and grapefruit juice because they inhibit CYP3A4 and raise lurasidone blood levels unpredictably, increasing akathisia, sedation, orthostatic hypotension, and other dose-related side effects. Drink sweet orange juice or other non-grapefruit beverages instead, take lurasidone with at least 350 calories of food, and tell your prescriber about any accidental grapefruit exposure.